Sponsor: Merck
Sponsor Study ID: MK2870-015
Study Title: A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physicians Choice in Third Line+ Advanced/Metastatic Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma
CTO #: 104009
NCT Number: NCT06356311
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Esophagus
Study Objectives: Primary: To compare MK-2870 to TPC with respect to OS Secondary: 1) To compare MK-2870 to TPC with respect to PFS per RECIST 1.1 as assessed by BICR 2) To compare MK-2870 to TPC with respect to ORR per RECIST 1.1 as assessed by BICR 3) To evaluate DOR per RECIST 1.1 as assessed by BICR in participants who demonstrate confirmed CR or PR during or after treatment with MK-2870 and TPC 4) To evaluate the safety and tolerability of MK-2870